| P50 | author | Roger A. Barker | Q60589802 |
| P2093 | author name string | Sarah L Mason | |
| P2860 | cites work | Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records | Q22306526 |
| | A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia | Q24515363 |
| | A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 |
| | An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease | Q28476789 |
| | An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease | Q28477159 |
| | Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data | Q30624346 |
| | Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study | Q30631995 |
| | Pharmacological management of Huntington's disease: an evidence-based review | Q33250216 |
| | Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators | Q33519733 |
| | Increased rate of suicide among patients with Huntington's disease | Q33620527 |
| | Pharmacological profile of HWA-131, a novel antiinflammatory agent with immunomodulating properties | Q33843024 |
| | Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease | Q33908944 |
| | Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data | Q34089875 |
| | Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias | Q34172000 |
| | Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial | Q34231219 |
| | Long-term effects of tetrabenazine in hyperkinetic movement disorders | Q34417087 |
| | Huntington's disease patients have selective problems with insight | Q34457803 |
| | Neurocognitive signs in prodromal Huntington disease | Q34474382 |
| | Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders | Q34585606 |
| | Suicidal behavior in prodromal Huntington disease | Q35268087 |
| | Huntington's disease from the patient, caregiver and physician's perspectives: three sides of the same coin? | Q36336471 |
| | Unintended effects of orphan product designation for rare neurological diseases. | Q36375543 |
| | Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia | Q36495584 |
| | Off label use of lithium in the treatment of Huntington's disease: A case series | Q36615521 |
| | Earliest functional declines in Huntington disease | Q36776679 |
| | Sleep deficits but no metabolic deficits in premanifest Huntington's disease | Q36799911 |
| | Patient and caregiver quality of life in Huntington's disease | Q37212835 |
| | Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease | Q37250382 |
| | Results of the citalopram to enhance cognition in Huntington disease trial | Q37649788 |
| | Dopamine and Huntington's disease. | Q38379277 |
| | A Double Blind Trial of Lithium Carbonate and Haloperidol in Huntington's Chorea | Q39740312 |
| | Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis | Q39809906 |
| | Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice | Q40436889 |
| | Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses | Q40753593 |
| | A controlled clinical trial of baclofen as protective therapy in early Huntington's disease | Q41265980 |
| | Riluzole in Huntington's disease (HD): an open label study with one year follow up. | Q42663375 |
| | Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. | Q43227123 |
| | A pilot study using nabilone for symptomatic treatment in Huntington's disease | Q43257764 |
| | Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease | Q43669934 |
| | High-dose olanzapine in Huntington's disease | Q43914849 |
| | Olanzapine in Huntington's disease | Q44004335 |
| | Rapid onset of tardive dyskinesia in Huntington disease with olanzapine | Q44097713 |
| | Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine | Q44131392 |
| | Minocycline for Huntington's disease: an open label study | Q44357409 |
| | Mirtazapine in suicidal Huntington's disease | Q44363449 |
| | Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. | Q44504149 |
| | Minocycline and doxycycline are not beneficial in a model of Huntington's disease | Q44533011 |
| | Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial | Q44616594 |
| | Paroxetine retards disease onset and progression in Huntingtin mutant mice | Q44817609 |
| | Minocycline in Huntington's disease: a pilot study | Q44936949 |
| | Minocycline safety and tolerability in Huntington disease | Q45013899 |
| | The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study | Q45288758 |
| | Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial | Q45289087 |
| | Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease. | Q45289512 |
| | A randomized trial of amantadine in Huntington disease | Q45289614 |
| | The effects of modafinil on mood and cognition in Huntington's disease | Q45289716 |
| | A study of chorea after tetrabenazine withdrawal in patients with Huntington disease | Q45289736 |
| | A Europe-wide assessment of current medication choices in Huntington's disease | Q45290250 |
| | The long-term effect of tetrabenazine in the management of Huntington disease | Q45291782 |
| | Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease | Q45292037 |
| | Health-related quality of life in Huntington's disease: Which factors matter most? | Q45292043 |
| | A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease | Q45292205 |
| | A controlled trial of remacemide hydrochloride in Huntington's disease | Q45292392 |
| | Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine | Q45292440 |
| | L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease | Q45292472 |
| | Apathy is not depression in Huntington's disease | Q45295281 |
| | Effectiveness of risperidone in Huntington chorea patients. | Q45297218 |
| | Treatment of depression in Huntington's disease with monoamine oxidase inhibitors | Q45298168 |
| | Serum haloperidol concentration and choreiform movements in Huntington's disease | Q45298686 |
| | Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. | Q45298962 |
| | Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice | Q45299471 |
| | Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease | Q45299623 |
| | The gait abnormality of Huntington's disease | Q45300030 |
| | Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial | Q45300094 |
| | Baclofen and lithium in Huntington's chorea | Q45300715 |
| | Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice | Q45300908 |
| | Improvement of Huntington's disease with olanzapine and valproate | Q45301330 |
| | Effect of donepezil on motor and cognitive function in Huntington disease | Q45302793 |
| | Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease. | Q45302976 |
| | Nabilone could treat chorea and irritability in Huntington's disease | Q45303424 |
| | Two years' follow-up of rivastigmine treatment in Huntington disease. | Q45304063 |
| | Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model | Q45304699 |
| | Tetrabenazine: for chorea associated with Huntington's disease | Q45305375 |
| | Riluzole in Huntington's disease: a 3-year, randomized controlled study | Q45305925 |
| | Lamotrigine in motor and mood symptoms of Huntington's disease | Q45306374 |
| | Weight gain and ghrelin level after olanzapine monotherapy | Q47394922 |
| | A comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study. | Q54348727 |
| | Unified Huntington's disease rating scale: Reliability and consistency | Q57422462 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| | pharmacotherapy | Q701216 |
| P304 | page(s) | 41-52 | |
| P577 | publication date | 2015-11-04 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature | |
| P478 | volume | 17 | |